Incyte Earnings Call Highlights Growth Beyond Jakafi

Incyte ((INCY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Incyte’s latest earnings call struck an optimistic tone, with management leaning into strong 2025 results and a visibly accelerating portfolio beyond Jakafi. While executives acknowledged rising R&D spend, trial complexity and specific setbacks such as the Opsilora PN program pause, they argued broad-based revenue growth and a deep late-stage pipeline more than offset execution risks.

Strong Revenue Acceleration in 2025

Incyte reported Q4 2025 revenues of $1.51 billion, up 28% year over year, with product sales at $1.22 billion, up 20%. For the full year, total revenues climbed 21% to $5.14 billion and product revenues rose 20% to $4.35 billion, underscoring solid commercial momentum heading into 2026.

Core Business Beyond Jakafi Ramps Up

The core business excluding Jakafi delivered about $1.26 billion in 2025 sales, a roughly 53% jump versus 2024. Management highlighted Opsilora, Nictimbo and Manjovi as the primary growth engines, reinforcing the narrative that Incyte is successfully building a diversified revenue base.

Jakafi Still Growing but Visibility Matters

Jakafi remained the workhorse with Q4 sales of $828 million, up 7% year over year, and full-year revenue of $3.093 billion, up 11%. Prescriptions increased 11% in Q4 and 9% for the year, and 2026 net sales are guided to $3.22–$3.27 billion, with scripts expected to grow in the high single digits.

Opsilora Maintains Strong Commercial Momentum

Opsilora posted Q4 net sales of $207 million, up 28%, and full-year revenue of $678 million, up 33%, with U.S. atopic dermatitis prescriptions up 24% and vitiligo up 15%. International vitiligo sales doubled to $130 million in 2025, the pediatric AD launch is already annualizing around $30 million, and 2026 sales are guided to $750–$790 million.

Hematology and Oncology Franchise Surges

Hematology and oncology product sales hit $187 million in Q4, up 121% year over year, and $583 million for 2025, up 83%. Nictimbo generated roughly $152 million in its first year from about 13,000 infusions, while Manjovi sales rose 20% on the follicular lymphoma launch and Phase III frontline DLBCL data showed a 25% progression-free survival benefit versus R‑CHOP.

Pipeline and Regulatory Engines in High Gear

Management emphasized a robust late-stage pipeline with 14 pivotal trials across seven assets expected to be running by the end of 2026. Recent regulatory moves include submissions for Jakafi XR, Opsilora and povastatinib MA in Europe, plus tafasitamab approvals in Europe and Japan backed by positive FRONT MIND Phase III results.

Oncology and Targeted Therapy Data Impress

Incyte’s KRAS G12D inhibitor seven34 delivered a 37% overall response rate and 78% disease control at the planned Phase III dose in largely late-line pancreatic cancer, with a first-line Phase III trial slated to start in early 2026. The company also initiated a Phase III trial of its TGFβ2 x PD‑1 bispecific in microsatellite stable colorectal cancer, underscoring ambition in difficult solid tumors.

2026 Outlook and Expense Discipline

For 2026, Incyte guided revenues to $4.77–$4.94 billion, implying 10–13% growth, with core ex‑Jakafi sales of $1.57–$1.69 billion, about 30% growth at the midpoint. GAAP R&D plus SG&A expenses are forecast at $3.495–$3.675 billion, a roughly 4% increase, with R&D up around 10% to support late-stage programs while SG&A remains broadly flat.

Opsilora PN Setback Clouds One Growth Path

One of two Phase III trials of Opsilora in prurigo nodularis failed to meet the primary itch endpoint, even as the other trial hit its goal. The FDA has indicated another efficacy study will be needed, prompting Incyte to pause PN development for now, which delays potential revenue and adds future cost and regulatory risk.

Rising R&D and Quarterly Volatility

GAAP R&D expense rose to $611 million in Q4, up 31% year over year, and reached $2.05 billion for 2025, with ongoing R&D up 8%. Management acknowledged that the heavy late-stage investment profile will elevate near-term expenses and could introduce quarterly volatility as the company juggles multiple pivotal programs.

Need to Backfill Jakafi Before Generic Entry

With Jakafi growth slowing to mid to high single digits and generics expected around 2028–2029, investors are focused on replacement revenue. Incyte must execute on launches and label expansions for Jakafi XR, povastatinib and the tafasitamab and Manjovi franchises, leaving meaningful execution risk if timelines slip or uptake disappoints.

Formulary and Pricing Tradeoffs Ahead

To widen access, Opsilora is taking price steps that will pressure average selling price in 2026 before easing in 2027. Management also cautioned that Jakafi XR is unlikely to secure top-tier formulary status initially, and with expected conversion of only 10–30%, there is uncertainty around how quickly volume and net pricing will ramp.

Clinical and Regulatory Uncertainties Persist

Several programs still depend on key regulatory and clinical milestones, including dosing strategies for nine89 across different CALR mutation types and potential NDA decisions and pivotal readouts. Management stressed that these late-stage events are binary in nature and could materially swing Incyte’s medium-term growth profile.

Placebo and Trial Design Complexity

Incyte highlighted challenges running trials in diseases with variable placebo responses such as hidradenitis suppurativa or milder patient populations. To manage this, the company is planning larger studies with tighter entry criteria, which may improve data quality but adds complexity, timelines and cost.

Forward-Looking Guidance Underscores Balanced Ambition

Looking ahead, the company expects 2026 to deliver double-digit revenue growth anchored by steady Jakafi expansion, mid-teens growth for Opsilora and roughly 40–50% growth in hematology and oncology. Management framed the modest 4% rise in operating expenses, including a 10% R&D lift focused on seven late-stage programs, as evidence of disciplined investment geared toward building a post-Jakafi portfolio.

In summary, Incyte’s call painted a picture of a company in active transition, trading near-term cost and trial risk for a broader, more durable growth engine beyond Jakafi. Investors will be watching closely as the company executes its dense 2026–2027 pipeline, but for now the strong revenue trends and deepening oncology and immunology franchises underpin a broadly constructive outlook.

Disclaimer & DisclosureReport an Issue